Information solutions provider Thomson Scientific, part of Thomson Corporation, US, has announced the release of Newport Horizon Premium and Newport Vision Premium. The new solutions are designed specifically for professionals working in product selection, business development, competitive intelligence and Active Pharmaceutical Ingredient (API) sourcing.
Newport Horizon Premium and Newport Vision Premium combine sales, launch, patent, patent challenge, exclusivity, chemistry, prescribing and regulatory information for more than 10,000 molecules, 18,000 companies, 67 markets and 90 patent countries worldwide with unique, early API development and manufacturing intelligence. They build on the substantial success of Horizon Global and Vision CI by adding kilogram and IU (International Units) API consumption data from IMS Health to the data and capabilities already available. This data will now be available for thousands of drugs by region and by dose form for both the current and previous year and will allow customers to evaluate scale, consumption trends and prices for active ingredients, all of which can be difficult to estimate using sales data alone.
Both Newport Horizon Premium and Newport Vision Premium seek to address the needs of large and small players in the pharmaceuticals market and feature powerful multi-criteria search functionalities. Newport Horizon Premium is aimed at helping generic, OTC and API companies in their constant struggle to build deals faster and accelerate time to market. Newport Vision Premium is focused on helping leading pharmaceutical companies evaluate the earliest signs of generic competition for their brands and identify back-up or alternative sources of API supply.
More News in this Theme
